BioNTech SE (BNTX) annual results, year to 31 December 2018: revenue EUR 128 million, from the 20-F
BioNTech SE files a 20-F with the SEC once a year, in euros. In the year to 31 December 2018 it reported revenue of EUR 128 million ($151 million at the year's average rate), up 107.1% on the year before. Its profit attributable to shareholders was EUR -48.0 million.
this yearthe year beforeIn euros as filed. Hover a bar for its figure.
Income statement (profit and loss)
Figures in
| Year to | Dec 2017 | Dec 2018 |
|---|---|---|
| Revenue | 61.6 | 128 |
| Cost of sales | 9.3 | 13.7 |
| Gross profit | 52.3 | 114 |
| Research and development | 85.5 | 143 |
| Operating profit | -61.3 | -53.9 |
| Finance costs | 26.0 | 0.0 |
| Profit before tax | -85.9 | -47.7 |
| Income tax | 0.0 | 0.6 |
| Profit for the year | -86.0 | -48.3 |
| Profit attributable to shareholders | -85.7 | -48.0 |
| Filing | 20-F | 20-F |
EUR million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read more
A line the company does not file under the standard tag is left out rather than estimated.Cash flow
| Year to | Dec 2017 | Dec 2018 |
|---|---|---|
| Cash from operations | -52.6 | -58.9 |
| Purchase of property, plant and equipment | 24.3 | 29.9 |
| Free cash flow | -76.9 | -88.8 |
| Cash from investing | -52.5 | -66.5 |
| Cash from financing | -1.6 | 365 |
| Depreciation and amortisation | 10.5 | 22.0 |
| Filing | 20-F | 20-F |
EUR million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet
| Year to | Dec 2017 | Dec 2018 |
|---|---|---|
| Funded by | ||
| Equity attributable to shareholders | -48.2 | 266 |
| Non-controlling interests | n/a | 0.8 |
| Borrowings, as filed | n/a | 0.0 |
| Lease liabilities | n/a | 50.8 |
| Other liabilities | n/a | 335 |
| Total equity and liabilities | n/a | 653 |
| Owned | ||
| Property, plant and equipment | 49.6 | 66.2 |
| Cash and cash equivalents | 172 | 412 |
| Inventories | n/a | 5.8 |
| Other assets | n/a | 169 |
| Total assets | n/a | 653 |
| Filing | 20-F | 20-F |
EUR million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2017 | Dec 2018 |
|---|---|---|
| Gross margin | 84.9% | 89.3% |
| Operating margin | -99.5% | -42.2% |
| Net margin | -139.1% | -37.6% |
| Free cash flow margin | -124.8% | -69.6% |
| Return on year-end equity | n/a | -18.0% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
The exchange rates used
| Year to | Average over the year US dollars per EUR | At the year end US dollars per EUR |
|---|---|---|
| Dec 2017 | 1.1301 | 1.2022 |
| Dec 2018 | 1.1817 | 1.1456 |
| Dec 2019 | 1.1194 | 1.1227 |
| Dec 2020 | 1.1410 | 1.2230 |
| Dec 2021 | 1.1830 | 1.1318 |
| Dec 2022 | 1.0534 | 1.0698 |
| Dec 2023 | 1.0817 | 1.1062 |
| Dec 2024 | 1.0820 | 1.0351 |
| Dec 2025 | 1.1306 | 1.1736 |
Converted by us, not by the company: the Federal Reserve's daily noon buying rates in New York (H.10), FRED series DEXUSEU.
Read more
Profit and loss, cash flow and EPS use the average of the daily rates over each fiscal year; the balance sheet uses the rate on the year end, or the last one before it. Ratios are the same in either currency. The filed figures are the ones in euros.20-F for the year to 31 December 2018, filed 30 March 2021: the filing. The figures are in euros as filed.